Brief: Athira Pharma To Present Additional Biomarker Data From Act-Ad Phase 2 Study Of Fosgonimeton At The 2022 Clinical Trials On Alzheimer’S Disease (Ctad) Conference

LeonaBio

21/11/2022 12:04

Nov 21 (Reuters) - Athira Pharma Inc  ATHA.O :
    * ATHIRA PHARMA TO PRESENT ADDITIONAL BIOMARKER DATA FROM
ACT-AD
PHASE 2 STUDY OF FOSGONIMETON AT THE 2022 CLINICAL TRIALS ON
ALZHEIMER’S DISEASE (CTAD) CONFERENCE

Source text for Eikon:  ID:nGNX7sPK5l 
Further company coverage:  ATHA.O 
 ((Reuters.Briefs@thomsonreuters.com;))